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Th e morbidity and mortality associated with atri-
al fi brillation (AF) are related mainly to ischaemic 
stroke, and the prevention of thrombo-embolism is an 
important component of the patient management [1]. 
Hospital admissions caused by AF have increased 
by more than 60% in the last 20 years [2]. About 3% 
of the population over the age of 45, about 4% of the 
general adult populations and 6% over age 65 has AF. 
After the age of 55, and with other risk factors such 
as diabetes, high blood pressure, and underlying heart 
disease the incidence of AF increase to doubles with 
each decade of life [3], and the number of people with 
AF is expected to double by 2050 [4g.
One of the main complications of AF is stroke, 
which is 3 to 5 times greater than individuals without 
AF, and stroke cause by AF is typicaly hardest of the 
other podtype in all of ages groups [5].
It’s estimated that AF is responsible for over 1500 
strokes each year in Serbia, and 150 in Monte Negro, 
1.5 times more frequently in males than in females. 
Prevention of stroke related to AF has enormous 
important. AF is a major risk factor for cardioembolic 
stroke, and the most frequent cardial cause of stroke. 
Although AF is relativy hard to identifi cation, stroke 
cause by AF is preventable. But, preventive measures 
are applied with a small number of patients. Up to three 
million people worldwide have a stroke related to AF 
every year, that is one person every 12 seconds! [6]. 
 Th e diff erent types of AF i.e. the classifi cation 
system in the direction of ESC 2010 Guidelines for 
the management of patients with AF are: fi rst de-
tected - only one diagnosed episode, paroxysmal - 
recurrent episodes that self-terminate in less than 7 
days, persistent - recurrent episodes that last more 
than 7 days, require cardio-conversion, long-standing 
persistent - >/= 1 year duration, and permanent - an 
ongoing long-term episode, to take from patient and 
doctor [7].
Diagnosis of AF is based on factors such as: signs/
symptoms, physical examination, and specifi c diag-
nostic studies that are used to confi rm the presence of 
the condition. AF is diagnosed by the doctor using a 
stethoscope in the fi rst instance. Th is will probably be 
followed by an ECG which will confi rm the irregu-
larity of the heartbeat.
Sometimes the patient wears a heart monitor for 
24 hours or even more. Th is will
detect any abnormal heart beats that may be 
caused by AF by recording all heart activity over a 
prolonged period. It is not always possible to rely on 
the pulse beat felt in the wrist to detect AF as not 
only will the heart beat irregularly, many heartbeats 
which can be heard by listening to the heart cannot 
be distinguished at the wrist. Th ey do not reach the 
wrist because the heart, contracting weakly, has not 
adequately fi lled with blood.
According to the Framingham Off spring Study 
2040 asymptomatic patients (without clinical signs 
for stroke) had MRI signs for ishemic stroke. Th e 
minimum of 1 silent stroke was to fi nd with 10.7% pa-
tients. Th e important numbers of silent stroke was be-
come associated with AF [8]. A silent stroke increase 
risk for stroke and for dementia, therefore existance of 
silent ishemia (infarct or lession in white masse): in-
crease risk of stroke for over than 3 time, independent 
risk factors from the others, and increase risk of de-
mentia 2,3 time, and become associated with higher 
damage of cognitive function [9].
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AF is a worst prognostic sign for hard stroke and 
early die exit. Analyzed result of 
85 patients with or without AF in the base of isch-
emic stroke after IV t-PA, after 7 and 90 days, group 
with AF was worst result - basic NIHSS was high-
er, having frequently of artery ocllusion at the basic 
MRA, and 2,3% symptomatic ICH on AF patients 
after IV t-PA [10]. Except that, in one of the other 
study with 49 patients analyzed early recanaliza-
tion after IV t-PA and neurological status (NIHSS): 
51,3% patients no early recanalization, 0/18 patients 
with recanalization had worsening of neurologic sta-
tus, 4/19 was without recanalization were worsening 
(p= 0,039), and conclused that AF are an independent 
predictor for no recanalization [11]. 
Approximately 20% of all strokes are caused by 
embolism. If left untreated, AF can increase your 
stroke risk from 4 to 6 times. Long-term untreated 
AF can also weaken the heart, leading to potential 
heart failure [12].
Major studies on AF have shown no real diff erence 
in mortality between rhythm- and rate-control strat-
egies. However, a rhythm-control strategy is some-
times needed to help control symptoms. Recent data 
from clinical trials and registries suggest that agents 
with both rhythm- and rate-controlling properties are 
eff ective at maintaining sinus rhythm, avoiding car-
diac and extracardiac side eff ects and improving qual-
ity of life [13].
 Until recently, vitamin K antagonists (VKAs) and 
aspirin were the only agents available for the preven-
tion of AF related stroke. However, many patients eli-
gible for anticoagulant therapy simply did not receive 
it. In addition, maintaining patients on VKAs within 
their target international normalized ratio range can 
be challenging in real-world practice. Recently, results 
have been reported for RE-LY and ROCKET-AF 
trials of novel oral anticoagulant agents in the pre-
vention of AF related stroke. Th ese agents off er the 
promise of addressing many of the challenges in VKA 
therapy with the hope of improving patient care (14). 
For the patients with AF diagnosis it’s a necessary 
education about AF in order to improve diagnosis and 
management. Education AF patients about stroke 
signs, as well as to plan eventual transport in emergen-
cy to the nearest stroke unit in order to receive acute 
stroke treatment, preparing food workshops based on 
warfarin diet information and safe recipes [15].
Th e choice of optimum antithrombotic therapy 
for a given patient depends on the risk of thrombo-
embolism, and the assessment of thrombo-embolic 
risk using validated stratifi cation schemes, such as the 
CHADS2 score, is a critical step. Improved stratifi ca-
tion schemes are needed that take into account the 
risk of intracerebral haemorrhage, which is the most 
worrisome complication of anticoagulant therapy. Th e 
pattern of AF (paroxysmal, persistent, or permanent) 
should not infl uence the selection of antithrombotic 
treatment. Similarly, successful rhythm control is not 
a sound basis for withdrawing antithrombotic treat-
ment, and whether this situation diff ers after success-
ful catheter ablation of AF has not been established. 
At present, oral vitamin K antagonists alone are 
recommended for patients with AF at moderate-to-
high risk of stroke. A combination of anticoagulant 
and antiplatelet drugs is necessary in patients with 
AF undergoing percutaneous coronary intervention 
and stent implantation, but the optimal therapeutic 
management of these patients has not been defi ned. 
Th e development of new antithrombotic agents that 
are easier to use and have a superior benefi t-to-risk 
ratio will extend treatment to a greater proportion of 
the AF population at risk. Th e large number of phase 
III trials currently investigating specifi c inhibitors of 
thrombin or factor Xa that do not require laboratory 
monitoring suggests that this goal is within reach (1).
 Friquent of ilness, and structure of the patients 
in the Serbian Experience with Th rombolysis in Isch-
emic Stroke (SETIS) were as follow: patients with AF 
participate with 18% (425 patients - 75 with AF), 29 
females in group with AF vs 119 in the others diag-
nostic categories, and 46 males with AF vs 231 with 
others diagnosis (χ2 0,59; p <0,1), averages age 65,12 
in group with AF vs 56,66 in the others diagnostic 
categories (t 6,61; p <<0,0001). Initial indicators, and 
early course of disease in the fi eld of initial clinical 
status for basic NIHSS were 14,9 among patients with 
AF, and 12,9 for the others (t 3,29; p 0,0012), initial 
radiologic status with ASPECTS were 9,05 among 
patients with AF vs 9,52 for the others (t -3,42; p 
0,0009), the time to begin of the threatment were 161 
minutes among AF patients, and 166 minutes for the 
others (t -0,78; p 0,43). Finally, early course of the 
treatment were with NIHSS after 24 hours 10,68 in 
the AF group, and 8,33 in the others diagnostics cat-
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egories (t 2,17; p 0,032). Among complications hae-
morrhage was important frequently on patients with 
AF (χ2 8.61; p<0.01), asymptomatic haemorrhage 9 
in the AF group vs 32 in the others (χ2 0.57; p>>0,1), 
and symptomatic haemorrhage 11 in the AF group vs 
14 in the others (χ2 12.65; p<< 0,001). Die exit were 
in 19% with AF patients vs 12% in the group with 
others diagnostic categories (χ2 2.81; p>0,05). State 
after three months e.i. recovery after 90 days were in 
AF group in 47% favorable vs 53% infavorable, and in 
the group with the others diagnostic categories in 56% 
favorable vs 44% infavorable results (χ2 2.16; p>0,1). 
In conclusion notes it’s can says that thrombolysis 
in patients with AF is equal
effi  casse as in the others patients from SETIS 
base. In addition, thrombolysis in patients with AF 
is less safe in relation on the others patients, to take 
into consideration important bigger number of symp-
tomatic ICH, which isn’t brought to higher lethality 
after 90 days. Reasons for less safety of thrombolyze 
in patients with AF can be come from facts: that pa-
tients with AF and stroke are important older, and 
they have important basic neurologic deffi  cit, and big-
ger brain infarct [16]. 
Th e most recent raport about treatment with the 
150-mg twice daily dose of dabigatran etexilate is 
equally safe and eff ective in patients with permanent, 
persistent, and paroxysmal atrial fi brillation, according 
to a new subgroup analysis of the Randomized Evalu-
ation of Long-Term Anticoagulant Th erapy (RE-LY) 
trial. Th e results were presented at the American Col-
lege of Cardiology (ACC) 2011 Scientifi c Sessions at 
the begining of April 2011.
Like the overall results from the 18 000-patient 
study, dabigatran 150 mg twice daily was more eff ec-
tive than warfarin for reducing the risk of stroke or 
systemic embolism, with a comparable risk of bleed-
ing, compared with the older anticoagulant. 
Investigators did observe slightly diff erent re-
sponses among patients treated with the 110-mg 
twice-daily dose, however, with dabigatran most ef-
fective in patients with paroxysmal AF and less so in 
patients with permanent AF. 
Among patients with permanent AF treated with 
the lower dose of dabigatran, the hazard ratio for the 
risk of stroke/systemic embolism was 1.13 (95% CI 
0.81-1.57), while there was a signifi cant 40% rela-
tive reduction in risk among paroxysmal-AF patients 
treated with dabigatran 110 mg twice daily [17]. 
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